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Background: Cervical cancer continues to threaten women’s health worldwide, and the incidence of cervical
adenocarcinoma (AD) is rising in the developed countries. Previously, we showed that glucose-regulated protein
58 (Grp58) served as an independent factor predictive of poor prognosis of patients with cervical AD. However,
the molecular mechanism underlying the involvement of Grp58 in cervical carcinogenesis is currently unknown.
Methods: DNA microarray and enrichment analysis were used to identify the pathways disrupted by
knockdown of Grp58 expression.
Results: Among the pathway identified, the WNT signaling pathway was one of those that were significantly
associated with knockdown of Grp58 expression in HeLa cells. Our experiments showed that β-catenin, a critical
effector of WNT signaling, was stabilized thereby accumulated in stable Grp58 knockdown cells. Membrane
localization of β-catenin was observed in Grp58 knockdown, but not control cells. Using a transwell assay, we
found that accumulated β-catenin induced by Grp58 knockdown or lithium chloride treatment inhibited the migration
ability of HeLa cells. Furthermore, an inverse expression pattern of Grp58 and β-catenin was observed in cervical tissues.
Conclusions: Our results demonstrate that β-catenin stability is negatively regulated by Grp58 in HeLa cells. Overexpression
of Grp58 may be responsible for the loss of or decrease in membranous β-catenin expression in cervical AD.Background
Cervical cancer is the third leading cause of cancer-
related mortality among women worldwide [1], although
records show a marked decline in incidence over the
past three decades. Despite a reducing in the incidence
of cervical squamous cell carcinoma (SCC), the fre-
quency of cervical adenocarcinoma (AD) is increasing
due to insufficient detection of cervical AD precursor
lesions with the Papanicolaou smear test [2]. Therefore,
identification of biomarkers specific for cervical AD is
essential for early detection and improved prognosis.
Persistent infection with high-risk human papillomavirus
(HPV) is the major risk factor for both SCC and AD [3].* Correspondence: khlin@mail.cgu.edu.tw
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unless otherwise stated.However, HPV alone is not sufficient to cause cervical
cancer; other molecular markers of cervical carcinogenesis
are essential. Previously, we demonstrated that glucose-
regulated protein 58 (Grp58) serves as an independent
prognostic factor for cervical AD, but not SCC [4]. Cell-
based studies revealed that Grp58 regulates the invasion
and metastatic ability of HeLa cells. Grp58 is a multi-
functional protein belonging to the disulfide isomerase
family of proteins [5]. The functions of Grp58 in quality
control of glycoprotein and major histocompatibility com-
plex class I (MHC class I) maturation are well docu-
mented [6]. Recent evidence has suggested that Grp58
plays a role in cancers [7,8], although the details are un-
clear. In the current investigation, we explored the role of
Grp58 in cervical AD progression and the molecular
mechanism underlying Grp58 function.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Pathway enrichment analysis
Pathway enrichment analysis of a set of differentially
expressed genes upon Grp58 knockdown was performed
using the GeneGo MetaCore analysis tool (GeneGo, St.
Joseph, MI). Genes displaying differential expression, by
comparing stable control and Grp58 knockdown cells,
greater than 1.2 fold were uploaded. A pathway map with
a false discovery rate of <0.01 was considered significant.
Cell lines and cultures
The human cervical cancer cell line, HeLa, was obtained
from the American Type Culture Collection (ATCC,
Number: CCL-2), and cultured as recommended. Stable
Grp58 knockdown cells were established as described
earlier [4]. For MG132 (Sigma-Aldrich, St. Louis, MO)
and LiCl (Sigma-Aldrich) treatment, cells were seeded and
incubated overnight. The culture medium was refreshed,
and MG132 (10 μM) or LiCl (20 or 40 mM) was added to
the culture medium at 4 and 24 h prior to harvest, respect-
ively. For the Boyden chamber assay, LiCl was added to the
upper and lower chambers during cell seeding. For analysis
of β-catenin degradation, cells were pre-treated with
MG132 for 4 h. The medium was refreshed and cyclohexi-
mide (CHX, 10 ng/ml; Sigma-Aldrich) was used to block
new protein synthesis. Cells were harvested at 0, 1, 2, and
4 h after treatment with CHX.
Real-time quantitative RT-PCR (qRT-PCR)
Total RNA was extracted from cells using TRIzol. The
first cDNA strand was synthesized using the superscript
III kit for RT-PCR (Life Technologies, USA). qRT-PCR
was performed using SYBR Green, as described previ-
ously [9]. The primer sequences for β-catenin were as
follows: forward, 5’-CCg CAA ATC ATg CAC CTT T-3’,
and reverse, 5’-CTg ATg TgC ACg AAC AAg CA-3’.
Primers used in supplementary data were listed in
Additional file 1: Supplementary Methods and Figures.
Western blot analysis
Western blot analysis was performed as described previ-
ously [10]. Anti-Grp58 rabbit polyclonal antibody (1:10,000
dilution; Atlas, Sigma-Aldrich, St. Louis, MO), anti-β-
catenin mouse monoclonal antibody (1:2000 dilution; E-5
clone; Santa Cruz Biotechnology Inc., Santa Cruz, CA)
and horseradish peroxidase-conjugated, affinity-purified
secondary antibody to rabbit or mouse (Santa Cruz
Biotechnology) were used. Immunocomplexes were vi-
sualized via chemiluminescence with an ECL detection
kit (Amersham, Piscataway, NJ).
Transwell assay
Cells were trypsinized and re-suspended using serum-
free medium. Equal amounts of cells (5×104 in 100 μl)were seeded in the upper chamber (Corning-Costar
3494 Transwell, Lowell, MA) in triplicate. Lower chambers
were supplemented with 20% fetal bovine serum in
medium. Traversed cells were stained with crystal violet
after 24 h incubation.
Immunofluorescence (IF) staining
Cells were seeded on glass slides, fixed with 3.7%
paraformaldehyde, permeabilized with 0.1% Triton X-100/
PBS (PBST) for 10 min, blocked with 1% bovine serum
albumin for 30 min, and stained with the indicated pri-
mary antibody for 3 h at RT. After washing three times
with PBST, slides were incubated with secondary anti-
body for 2 h at RT. Fluorescence images were acquired
using confocal microscopy (ZEISS LSM 510 META, Carl
Zeiss Inc., Oberkochen, Germany). Grp58 and β-catenin
primary antibodies were the same as those used for
Western blotting. The secondary antibodies employed
were Alexa Fluor 488 goat-anti-mouse and 568 goat-
anti-rabbit antibody (Invitrogen Co., Carlsbad CA).
Immunohistochemistry (IHC) staining
Formalin-fixed and paraffin-embedded tissues were ex-
amined using IHC, according to previously described
procedures [11]. The Grp58 (Atlas, 1:2000 dilution) and
β-catenin (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA; 1:100 dilution) antibodies were used, along with
horseradish peroxidase-conjugated anti-rabbit and anti-
mouse secondary antibodies (Santa Cruz). Immunocom-
plexes were visualized using the Envision kit (DAKO,
Carpinteria, CA). Brown-colored cytoplasmic patches
were considered Grp58-positive. Slides were scored sep-
arately by two independent pathologists (Y.L and S.M.J)
blinded to all clinical data. Staining intensity was graded
as absent (0), weak (1+), medium (2+) or strong (3+).
The histoscore (Q) was calculated by multiplying the
percentage (P) of positive cells by intensity (I), according
to the formula: Q = P × I. The mean Q of each cervical
cancer type was selected as the cut-off value to divide
the high/low expression groups, as described previously.
Study population
Data from a total of 109 cervical carcinoma patients
subjected to primary definitive surgery between 2000
and 2008 at Chang Gung Memorial Hospital (Taoyuan,
Taiwan) were retrieved from the hospital database, and
the histological types confirmed by pathologists. Thirty-
four patients with cervical AD, classified as stage I to IIB
according to the International Federation of Gynecology
and Obstetrics (FIGO) staging system, were enrolled
under the protocol approved by the Institutional Review
Board (IRB: 95-1241B); all patients provided informed
consent. The personal rights of the patients were
preserved.
Table 1 Pathway map enrichment analysis
# Maps Maps folder p value
1 Granzyme A signaling Apoptosis and survival 6.81E-08





3 Antigen presentation by
MHC class I
Immune response 3.65E-07
4 IGF-1 receptor signaling Development 4.78E-06






7 ATM/ATR regulation of G1/S
checkpoint
DNA damage 1.34E-05
8 LRRK2 in neurons in
Parkinson's disease
1.77E-05
9 GM-CSF signaling Development 1.94E-05
10 Endothelial cell contacts
by junctional mechanisms
Cell adhesion 1.98E-05
11 Cytoskeleton remodeling Cytoskeleton
remodeling
2.64E-05










15 WNT signaling pathway. Part 2 Development 1.84E-04
16 WNT signaling pathway. Part 1.
Degradation of beta-catenin
in the absence WNT signaling
Development 1.92E-04
17 TGF-beta-dependent induction
of EMT via SMADs
Development 2.03E-04
18 Mismatch repair DNA damage 2.63E-04
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One-way analysis of variance (ANOVA) was used to com-
pare means of more than two groups. Mann–Whitney test
was applied to compare the means of two independent
groups. P values < 0.05 were considered significant. SPSS
statistical software was used for statistical analyses.
Results
Altered WNT signaling pathway in Grp58-knockdown
HeLa cells
Previously, we used an Affymetrix microarray to identify
the genes disrupted upon knockdown of Grp58 expres-
sion [4]. Differentially expressed genes were assessed
with the MetaCore pathway analysis tool. A total of
1218 Affymetrix probe IDs (fold change > 1.2 and <0.8)
were imported, among which 1208 were identified. Eight-
een pathway maps were significantly enriched based
on the differentially expressed genes (false discovery
rate < 0.01), which are listed in Table 1. Intriguingly,
three WNT-related maps (listed in 2, 15 and 16 of
Table 1) were enriched. The Wnt signaling pathway,
originally discovered in Drosophila, is highly con-
served among species. Wnt signaling regulates diverse
processes during embryo development, maintenance of
tissue homeostasis, and pathological conditions, in-
cluding cancer [12]. Several WNT signaling pathway-
related genes, including frizzled drosophila homolog of
10, disheveled homolog 1, casein kinase I epsilon and
casein kinase II alpha chain, and WNT signaling target
genes, including Myc, CD44, lymphoid enhancer-binding
factor 1, and vimentin, were disrupted in Grp58 knockdown
cells [4]. The mRNA and protein levels of several differen-
tially expressed genes were verified using real-time quanti-
tative RT-PCR (qRT-PCR) and Western blot analysis,
respectively (Additional file 2: Figure S1A, B).
Grp58 regulates β-catenin protein stability
β-Catenin is a crucial molecule of the WNT signaling
pathway. The β-catenin-dependent canonical pathway is
the Wnt signaling pathway that has been extensively
characterized to date. β-catenin transduces Wnt-activated
signals to the nucleus and serves as a transcriptional
co-activator in T cell factor/lymphoid enhancer-binding
factor (TCF/LEF)-dependent gene transcription [13]. Sev-
eral β-catenin target genes, such as L1 cell adhesion mol-
ecule (L1CAM) [14], laminin β-3 (LAMB3) [15], LEF1
[16], Myc [17] and S100A4 [18] were identified in our
DNA microarray analysis. In view of this finding, it is pro-
posed that the Wnt-β-catenin canonical pathway is regu-
lated upon knockdown of Grp58 expression. Consistent
with this theory, increased β-catenin-TCF transactivation
activity was observed in stable Grp58 knockdown cells
(G#1 and G#2, Additional file 2: Figure S1C). Accordingly,
the β-catenin mRNA and protein levels in Grp58knockdown cells were examined. As shown in Figure 1A,
β-catenin protein was more abundant in stable Grp58
knockdown cells (G#1 and G#2), compared to control
cells (L#1 and L#2). However, no significant differences in
β-catenin mRNA levels were observed between the cell
groups (Figure 1B), explaining why β-catenin was not
identified in microarray analysis. We propose that Grp58
regulates β-catenin expression via modulating protein
stability, but not gene transcription. β-Catenin protein
expression was indistinguishable in control and knock-
down cells treated with MG132, a proteasome inhibitor
(Figure 1C). The half-life of β-catenin was subsequently
analyzed. CHX was used to block new synthesis of pro-
tein. Notably, the β-catenin protein was stabilized and
accumulated in Grp58 knockdown cells after 4 h of
CHX treatment (Figure 1D, lanes 15 and 16). In con-
trast, traces of β-catenin were barely detectable in con-
trol cells at this time-point (Figure 1D, lanes 13 and
Figure 1 β-catenin protein is accumulated in Grp58 knockdown cells. Grp58 and β-catenin protein levels in stable Grp58 knockdown cells
were determined using Western blot (A, C and D) and qRT-PCR (B). (C) Cells were pretreated with vehicle control (DMSO) or MG132 for 4 h
before harvest. (D) β-Catenin degradation assay. After pre-treatment with MG132 for 4 h, the medium was refreshed. Cells were subsequently
treated with CHX and harvested at the indicated time-points. L#1 and L#2, HeLa cell lines stably expressing luciferase shRNA; G#1 and G#2, HeLa cell
lines stably expressing Grp58 shRNA.
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protein degradation, but not gene transcription, in
HeLa cells.β-catenin accumulates in cell-cell adherens of
Grp58-knockdown HeLa cells
In general, β-catenin mainly localizes to the cytoplasmic
membrane as a component of adherens junctions. Sub-
cellular localization of β-catenin in stable HeLa cells was
determined using IF staining, with images visualized using
confocal microscopy. As shown in Figure 2, Grp58 was
mainly located in the endoplasmic reticulum (ER), consist-
ent with previous reports [7,19]. Notably, broad mem-
branous staining of β-catenin was observed in Grp58
knockdown, but not control, cells.β-catenin inhibits HeLa cell migration
To explore the impact of stable accumulated β-catenin
on cell migration, the GSK3 inhibitor, LiCl, was used to
suppress β-catenin protein degradation. LiCl enhanced
β-catenin protein levels in a dose-dependent manner
(Figure 3A). The migration abilities of cells treated with
LiCl were further determined. As shown in Figure 3B, the
migration abilities of L#1 and L#2 cells were significantlyinhibited, along with β-catenin accumulation, in the pres-
ence of LiCl (Figure 3B). Consistent results were obtained
with the Transwell invasion assay (Ref. [4] and Additional
file 3: Figure S2A). The results indicate that β-catenin in-
duced by Grp58 knockdown or LiCl treatment suppresses
the migration ability of HeLa cells.Inverse expression patterns of Grp58 and β-catenin are
observed in cervical cancer
Loss of membranous β-catenin is a common feature of
various tumors, including cervical AD [20,21]. Thus, ex-
pression patterns of β-catenin in our study population
were determined. Intense β-catenin membranous stain-
ing was observed in adjacent normal epithelium, and most
AD samples showed incomplete membranous staining
(Figure 4A). As shown in Figure 4B, the β-catenin mean
histoscore (Q, mean ± standard deviation) of adjacent nor-
mal tissues (149.5 ± 83.2) was significantly higher than
that of tumor tissues (92.1 ± 62.3; Mann–Whitney test,
P = 0.014). Conversely, the Grp58 level was significantly
higher in tumors (186.2 ± 60) than adjacent normal tissues
(29.5 ± 56.3; P < 0.001). In paired samples (Figure 4B,
linked with lines), increased Grp58 histoscores were ob-
served in all tumor tissues, compared with non-tumor
Figure 2 Distribution of Grp58 and β-catenin in cervical cancer cells. Grp58 and β-catenin immunoreactive signals of control (upper panel,
L#1) and Grp58 knockdown (lower panel, G#2) cells were captured with confocal microscopy.
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in 82.6 % tumor tissues. An inverse trend was evident in
the expression of Grp58 and β-catenin. IHC staining
for Grp58 and β-catenin was additionally applied to a
commercial tissue microarray (TMA; CXC2281, Pan-
tomics Inc., Hilltop Drive, CA). Grp58 was significantlyFigure 3 Cell migration ability is inhibited by β-catenin. (A) Western b
cells with or without LiCl (20 and 40 mM) for 24 h. (B) The transwell assay
Left panel, images of traversed cells; Right panel, Quantitative results of theoverexpressed in AD (214.6 ± 78.4), compared with non-
tumor epithelium (72 ± 70.1; P = 0.005), while β-catenin
was significantly downregulated in AD (Q of AD and non-
tumor epithelium were 161.7 ± 69.8 and 242 ± 53.1,
respectively; P = 0.035; Figure 4C). This result was
consistent with findings for our study population.lot was used to determine β-catenin protein levels after treatment of
was used to determine the migration abilities of cells treated with LiCl.
transwell assay; **, P < 0.01.
Figure 4 Grp58 and β-catenin expression patterns in cervical AD. (A) IHC staining for Grp58 and β-catenin was performed in 34 cervical AD
patients. (B) The scatter plot shows Grp58 and β-catenin histoscores of 34 AD patients. The matched paired samples were linked with lines.
(C) Expression of Grp58 and β-catenin was determined by performing IHC with commercial TMA. Among all 228 cases, 5 non-tumor epithelium
tissues and 23 AD tissues in stage I to II tumors were scored. N, non-tumor tissue; T, tumor tissue; *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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was further validated in another cohort (Figure 4C).
Discussion
β-Catenin is a protein with ambivalent functions. It
serves as an adherent molecule to maintain epithelial
phenotype of cell thereby inhibiting cell invasiveness. On
the other hand, it is found in the nucleus together with
LEF-1 transcription factor to drive a variety of target
genes, such as epithelial-mesemchymal transition regu-
lated genes, thereby enhances cell invasiveness [22,23].
The present study of Grp58 regulation of cell invasive-
ness in cervical AD demonstrated that β-catenin is stabi-
lized thereby accumulates in the membrane in Grp58
knockdown HeLa cells, thereby inhibiting migration
ability. To our knowledge, this is the first study to pro-
vide evidence that Grp58 regulates WNT signaling. In
our microarray experiment, several genes downstream of
the WNT canonical pathway were identified. Howeverthis phenomenon appears to reflect a nuclear rather than a
plasma membrane adherent function of β-catenin. Indeed,
membrane-targeted β-catenin has been shown to increase
the concentration of cytosolic β-catenin, which is necessary
for transduction signals to the nucleus [24]. Nuclear
β-catenin is thought to play an oncogenic role in
tumorigenesis. However, earlier studies suggest that
some potent invasion-promoting genes, such as S100A4
and NEDD9, are inhibited by the WNTcanonical pathway
[25]. Shtutman et al. demonstrated that induction of pro-
gressive multifocal leukoencephalophthy by β-catenin sup-
presses the tumorigenicity of renal carcinoma cells [26].
Microarray analysis led to the identification of S100A4 as
a downregulated gene in the current study. The S100A4
protein level was verified using Western blot analysis
(Additional file 2: Figure S1B). Decreased S100A4 expres-
sion may result in attenuation of migration and invasion
abilities. However, restoration of S100A4 expression was
not sufficient to rescue the migration and invasion
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key molecules involved in Grp58-β-catenin-mediated
regulation of cell invasiveness is thus of considerable
interest.
Abnormal β-catenin expression, observed as loss of or
reduced membranous staining, is a common feature of
cervical cancer [21,27], and alterations in β-catenin-related
cell adherence are thought to be involved in cervical car-
cinoma pathogenesis [20]. In our study, all β-catenin posi-
tive staining cases shown a membranous fashion and
nuclear staining of β-catenin was not observed in any
cases. This result is identical with previous studies in cer-
vical AD [20,21]. β-Catenin function as a transcription acti-
vator may prefer to be an adhesion molecule in early stage
cervical AD. Therefore, the accumulated β-catenin induced
by Grp58 depletion or LiCl appears to play the adherent
role and inhibited HeLa cell invasiveness. In our study
population, membranous β-catenin was significantly de-
creased in a large proportion of AD tissues, compared to
adjacent normal epithelium, which served as the normal
control since the adjacent normal columnar epithelium
was rarely observed on the tissue slide. Conversely, Grp58
was overexpressed in AD. We observed inverse expression
patterns of Grp58 and β-catenin in our clinical specimens
as well as a commercial TMA. In the cell-based study,
knockdown of Grp58 expression resulted in accumulation
of β-catenin around the plasma membrane of cells. Based
on these results, we speculated that Grp58 acts as a regula-
tor of β-catenin protein distribution and stability in cancer
cells.
A previous study by our group demonstrated that
Grp58 serves as an independent factor for cervical AD
but not SCC [4]. Accordingly, we investigated the role of
Grp58 in the cervical AD cell line HeLa. A migration
assay was additionally performed with Caski and C33A,
two SCC cell lines with Grp58 knockdown, as well as
control cells without Grp58 knockdown. Migration abil-
ities were moderately affected in the Grp58 knockdown
cell lines, compared to control cells (Additional file 4:
Figure S3). The regulatory effect of Grp58 on cell migra-
tion may thus be more significant in AD than SCC.
One of the most widely studied functions of Grp58
is its role in the immune system. Grp58 participation in
MHC class I antigen presentation is well documented
[28]. Consistent with this, the “Antigen presentation by
MHC class I” pathway was the third most significantly
enriched in our microarray analysis. Alterations in adap-
tive immune responses have been reported in cervical
cancer [29]. Additionally, Cromme et al. demonstrated
that MHC class I is downregulated in metastases from
cervical carcinoma compared with the primary tumors
[30]. Therefore, we speculated that Grp58 regulates the
adaptive immune response to augment cancer invasion.
Granzyme A (GZMA) signaling was the most significantlyaffected pathway in our enrichment analysis which is
mainly attributed to differential expression of SET com-
plex, the central component in the GZMA pathway
(Table 1 and ref. [4]). Four members of the SET complex,
including SET, high mobility group box 2 (HMGB2), APEX
nuclease 1 (APEX1) and acidic leucine-rich nuclear
phosphoprotein 32 family member A (ANP32A), are
affected by Grp58 silencing [4]. SET complex responses
to GZMA and oxidative stress represents in tumors to
regulate cell apoptosis [31]. Downregulation of homeo-
static ER stress responses via knockdown of Grp58 expres-
sion appears to enhance apoptosis induced by oxidative
stress-inducing drugs [32]. Accordingly, knockdown of
Grp58 expression may disrupt ER homeostasis, resulting in
accumulation of oxidative stress and changes in the status
of the SET complex. The detailed molecular mechanism
underlying Grp58-mediated apoptosis is unclear. It would
be of interest to determine whether Grp58 regulates apop-
tosis through the SET complex and associated proteins
that participate in cervical cancer progression and drug
resistance.
Conclusions
Patients with cervical AD are generally considered to have
a poorer prognosis than those with SCC [33]. However,
knowledge of the natural history and optimal management
of cervical AD is limited. Early detection, prognosis and
treatment strategies specific to AD should be explored in
future studies. Previously we identified Grp58 as an inde-
pendent prognostic marker for cervical AD [4]. Here we
have demonstrated that Grp58 appears to regulate WNT
signaling by targeting β-catenin to augment cancer inva-
sion. Regulation of the immune response and free radical
homeostasis are possible mechanisms underlying cervical
cancer progression. Further research is warranted to de-
termine the detailed mechanism of Grp58 action in cer-
vical cancer progression.
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